Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Maruho, Nielsen Ink Licensing Deal for Common Warts Therapy in Asia
November 5, 2025
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
- Mundipharma’s Anerem 20 mg Now Available in Japan
November 5, 2025
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
- Toho Adopts Poison Pill in Response to 3D’s Rising Stake
November 4, 2025
- Meiji-Daito Consortium Discussing Integration of 56 Generic Products
November 4, 2025
- J&J Seeks Nod for Talvey-Tecvayli Bispecific Combo in Multiple Myeloma
November 4, 2025
- Alpha Fusion Launches PI of Lead Radiopharmaceutical in Thyroid Cancer
November 4, 2025
- Ayumi to Take Over Astellas, Ono Osteoporosis Drugs
November 4, 2025
- Fuji Inks Deal with Daiichi on Ranmark Biosimilar, Now Plans 2026 Launch
November 4, 2025
- Otsuka Snags APAC Rights to 4DMT’s AMD Gene Therapy
November 4, 2025
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
- Boehringer Bags Rights to Kyowa Kirin’s Preclinical Autoimmune Program
October 31, 2025
- Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…